Hence, one might assume that ataxia‐related protein‐aggregation pathologies caused by the presence of pathological variants in ataxia genes encoding cytoplasmic chaperones (BBS10, BBS12, DNAJC5, MKKS, and SACS) or protein‐clearance factors (such as IRF2PBL, LRSAM1, PEX2, PEX10, RNF216, STUB1, UBA5, and UCHL1) might benefit from PRE084‐treatment resulting in reduced build‐up of (toxic) protein‐aggregates (see Supplemental Material). The gene discussed is RNF216; the disease is Ataxia.